Get the Stockscreener App
2.53
4.89%
-0.13
Annexon Inc stock is traded at $2.53, with a volume of 892.24K.
It is down -4.89% in the last 24 hours and down -15.95% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.66
Open:
$2.65
24h Volume:
892.24K
Relative Volume:
0.70
Market Cap:
$277.57M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.4294
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-5.60%
1M Performance:
-15.95%
6M Performance:
-64.86%
1Y Performance:
-56.15%
1-Day Range:
$2.42
$2.69
1-Week Range:
$2.42
$2.825
52-Week Range:
$2.39
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.53 | 277.57M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash (NASDAQ:ANNX) - Seeking Alpha
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Analysts - Defense World
Rhumbline Advisers Purchases 5,854 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Q1 Earnings Forecast for Annexon Issued By HC Wainwright - Defense World
Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating - TipRanks
Analysts Set Expectations for Annexon FY2025 Earnings - Defense World
Q2 Earnings Estimate for Annexon Issued By HC Wainwright - Defense World
New York State Common Retirement Fund Purchases 20,311 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Potential Price Increase for Annexon Inc (ANNX) After Recent Insider Activity - Knox Daily
Annexon stock price target cut to $20 at H.C. Wainwright By Investing.com - Investing.com Canada
Annexon (NASDAQ:ANNX) Given “Buy” Rating at Needham & Company LLC - Defense World
Gaining Ground: Annexon Inc (ANNX) Closes Lower at 2.39, Down -9.47 - The Dwinnex
Promising Developments in Annexon Biosciences’ Pipeline Drive Buy Rating - TipRanks
Annexon Biosciences Reports Strong Progress in 2024 - MSN
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones - The Manila Times
Annexon reports Q4 EPS (33c), consensus (29c) - TipRanks
Annexon Reports Fourth Quarter and Year-End 2024 Financial - GlobeNewswire
Can Annexon's $312M War Chest Fuel Its Breakthrough Treatments Through 2026? - StockTitan
Annexon stock hits 52-week low at $2.63 amid market challenges - Investing.com Australia
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
What Will Annexon Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Annexon stock hits 52-week low at $2.63 amid market challenges By Investing.com - Investing.com South Africa
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon, Inc. (NASDAQ:ANNX) CEO Sells $14,811.95 in Stock - MarketBeat
Annexon executive sells shares worth $16,379 By Investing.com - Investing.com South Africa
Annexon EVP Ted Yednock sells $24,283 in stock - Investing.com India
Annexon chief medical officer sells $16,342 in common stock By Investing.com - Investing.com South Africa
Annexon chief medical officer sells $16,342 in common stock - Investing.com
Annexon chief business officer sells $19,523 in company stock By Investing.com - Investing.com Australia
Annexon executive sells shares worth $16,379 - Investing.com
Annexon chief business officer sells $19,523 in company stock - Investing.com
Annexon CFO Jennifer Lew sells shares worth $20,183 By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 - Investing.com
Annexon CFO Jennifer Lew Sells Shares to Cover Tax Obligations - TradingView
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Annexon EVP sells $4,260 in stock to cover tax obligations - Investing.com India
Annexon EVP sells $4,260 in stock to cover tax obligations By Investing.com - Investing.com Canada
Annexon EVP Ted Yednock sells $5,331 in stock By Investing.com - Investing.com Canada
Annexon CFO Jennifer Lew sells $5,322 in stock By Investing.com - Investing.com South Africa
Annexon EVP Ted Yednock sells $5,331 in stock - Investing.com
Annexon CFO Jennifer Lew sells $5,322 in stock - Investing.com
Annexon CEO Love Douglas sells $14,811 in stock - Investing.com
Annexon CEO Love Douglas sells $14,811 in stock By Investing.com - Investing.com South Africa
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):